The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
MeSH Review

Ovarian Diseases

Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of Ovarian Diseases


High impact information on Ovarian Diseases


Chemical compound and disease context of Ovarian Diseases


Biological context of Ovarian Diseases

  • Successful induction of ovulation and conception with combined gonadotropin-releasing hormone agonist plus highly purified follicle-stimulating hormone in patients with polycystic ovarian disease [16].
  • PCA analysis allowed correct separation of all serum specimens from 38 patients with EOC (100%) from all of the 21 premenopausal normal samples (100%) and from all the sera from patients with benign ovarian disease (100%) [17].
  • Administration of 4 mg of the antiprogestagen RU486 to 4-day-cyclic rats over 8 consecutive days starting on the day of estrus (Day 1) induced and anovulatory cystic ovarian condition with endocrine and morphological features similar to those exhibited in polycystic ovarian disease (PCO) [18].
  • To evaluate the role of altered luteinizing hormone (LH) release in the mechanism of polycystic ovarian disease (PCOD) anovulation, we have co-administered a gonadotrophin-releasing hormone (GnRH) antagonist and pulsatile GnRH therapy to two clomiphene citrate-resistant PCOD patients [19].
  • Serum gonadotropin, estrogen, and androgen levels were measured in samples obtained from 19 patients with polycystic ovarian disease (PCO) and from 10 normal women on day 2 to 4 of their menstrual cycles [20].

Anatomical context of Ovarian Diseases


Gene context of Ovarian Diseases


Analytical, diagnostic and therapeutic context of Ovarian Diseases


  1. Insulin signalling and the regulation of glucose and lipid metabolism. Saltiel, A.R., Kahn, C.R. Nature (2001) [Pubmed]
  2. Lack of association of the common immunologically anomalous LH with endometriosis. Gazvani, R., Pakarinen, P., Fowler, P., Logan, S., Huhtaniemi, I. Hum. Reprod. (2002) [Pubmed]
  3. Serum levels of tumor necrosis factor (TNF), soluble receptors for TNF (55- and 75-kDa sTNFr), and soluble CD14 (sCD14) in epithelial ovarian cancer. Gadducci, A., Ferdeghini, M., Castellani, C., Annicchiarico, C., Gagetti, O., Prontera, C., Bianchi, R., Facchini, V. Gynecol. Oncol. (1995) [Pubmed]
  4. Treatment of hirsutism with flutamide and a low-dosage oral contraceptive in polycystic ovarian disease patients. Ciotta, L., Cianci, A., Marletta, E., Pisana, L., Aglianò, A., Palumbo, G. Fertil. Steril. (1994) [Pubmed]
  5. Macrophage contributions to ovarian function. Wu, R., Van der Hoek, K.H., Ryan, N.K., Norman, R.J., Robker, R.L. Hum. Reprod. Update (2004) [Pubmed]
  6. CD40 ligand in pathogenesis of autoimmune ovarian disease of day 3-thymectomized mice: implication for CD40 ligand antibody therapy. Sharp, C., Thompson, C., Samy, E.T., Noelle, R., Tung, K.S. J. Immunol. (2003) [Pubmed]
  7. Induction and immunohistology of autoimmune ovarian disease in cynomolgus macaques (Macaca fascicularis). Bagavant, H., Sharp, C., Kurth, B., Tung, K.S. Am. J. Pathol. (2002) [Pubmed]
  8. Murine autoimmune oophoritis, epididymoorchitis, and gastritis induced by day 3 thymectomy. Immunopathology. Tung, K.S., Smith, S., Teuscher, C., Cook, C., Anderson, R.E. Am. J. Pathol. (1987) [Pubmed]
  9. Menstrual irregularity in women with acromegaly. Kaltsas, G.A., Mukherjee, J.J., Jenkins, P.J., Satta, M.A., Islam, N., Monson, J.P., Besser, G.M., Grossman, A.B. J. Clin. Endocrinol. Metab. (1999) [Pubmed]
  10. Comparison of luteinizing hormone pulsatility in the serum of women suffering from polycystic ovarian disease using a bioassay and five different immunoassays. Imse, V., Holzapfel, G., Hinney, B., Kuhn, W., Wuttke, W. J. Clin. Endocrinol. Metab. (1992) [Pubmed]
  11. Comparative effects of cyproterone acetate or a long-acting gonadotropin-releasing hormone agonist in polycystic ovarian disease. Couzinet, B., Le Strat, N., Brailly, S., Schaison, G. J. Clin. Endocrinol. Metab. (1986) [Pubmed]
  12. Enhanced disparity of gonadotropin secretion by estrone in women with polycystic ovarian disease. Chang, R.J., Mandel, F.P., Lu, J.K., Judd, H.L. J. Clin. Endocrinol. Metab. (1982) [Pubmed]
  13. Testosterone, dehydroepiandrosterone, and dehydroepiandrosterone sulfate in hyperandrogenic women. Steinberger, E., Smith, K.D., Rodriguez-Rigau, L.J. J. Clin. Endocrinol. Metab. (1984) [Pubmed]
  14. The effect of bromocriptine on gonadotropin and steroid secretion in polycystic ovarian disease. Steingold, K.A., Lobo, R.A., Judd, H.L., Lu, J.K., Chang, R.J. J. Clin. Endocrinol. Metab. (1986) [Pubmed]
  15. Histopathological effects of exogenously administered testosterone in 19 female to male transsexuals. Futterweit, W., Deligdisch, L. J. Clin. Endocrinol. Metab. (1986) [Pubmed]
  16. Successful induction of ovulation and conception with combined gonadotropin-releasing hormone agonist plus highly purified follicle-stimulating hormone in patients with polycystic ovarian disease. Lanzone, A., Fulghesu, A.M., Spina, M.A., Apa, R., Menini, E., Caruso, A., Mancuso, S. J. Clin. Endocrinol. Metab. (1987) [Pubmed]
  17. Detection of epithelial ovarian cancer using 1H-NMR-based metabonomics. Odunsi, K., Wollman, R.M., Ambrosone, C.B., Hutson, A., McCann, S.E., Tammela, J., Geisler, J.P., Miller, G., Sellers, T., Cliby, W., Qian, F., Keitz, B., Intengan, M., Lele, S., Alderfer, J.L. Int. J. Cancer (2005) [Pubmed]
  18. RU486-treated rats show endocrine and morphological responses to therapies analogous to responses of women with polycystic ovary syndrome treated with similar therapies. Ruiz, A., Aguilar, R., Tébar, A.M., Gaytán, F., Sánchez-Criado, J.E. Biol. Reprod. (1996) [Pubmed]
  19. The combination of gonadotrophin-releasing hormone (GnRH) antagonist and pulsatile GnRH normalizes luteinizing hormone secretion in polycystic ovarian disease but fails to induce follicular maturation. Dubourdieu, S., Le Nestour, E., Spitz, I.M., Charbonnel, B., Bouchard, P. Hum. Reprod. (1993) [Pubmed]
  20. Circulating gonadotropins, estrogens, and androgens in polycystic ovarian disease. DeVane, G.W., Czekala, N.M., Judd, H.L., Yen, S.S. Am. J. Obstet. Gynecol. (1975) [Pubmed]
  21. Luteinizing hormone receptors in ovarian follicles of patients with polycystic ovarian disease. Rajaniemi, H.J., Rönnberg, L., Kauppila, A., Ylöstalo, P., Vihko, R. J. Clin. Endocrinol. Metab. (1980) [Pubmed]
  22. Immunogenicity and contraceptive potential of a human zona pellucida 3 peptide vaccine. Bagavant, H., Fusi, F.M., Baisch, J., Kurth, B., David, C.S., Tung, K.S. Biol. Reprod. (1997) [Pubmed]
  23. Total renin after gonadotropin stimulation in polycystic ovarian disease. Matinlauri, I., Anttila, L., Jaatinen, T.A., Koskinen, P., Aalto, M., Irjala, K., Nikkanen, V. Fertil. Steril. (1995) [Pubmed]
  24. Autoimmune hypogonadism as part of an autoimmune polyglandular syndrome. Maclaren, N., Chen, Q.Y., Kukreja, A., Marker, J., Zhang, C.H., Sun, Z.S. J. Soc. Gynecol. Investig. (2001) [Pubmed]
  25. Ovarian electrocauterization causes LH-regulated but not insulin-regulated endocrine changes. Tiitinen, A., Tenhunen, A., Seppälä, M. Clin. Endocrinol. (Oxf) (1993) [Pubmed]
  26. Glucocorticoid metabolism and reproduction: a tale of two enzymes. Michael, A.E., Thurston, L.M., Rae, M.T. Reproduction (2003) [Pubmed]
  27. Oral contraceptives increase insulin-like growth factor binding protein-1 concentration in women with polycystic ovarian disease. Suikkari, A.M., Tiitinen, A., Stenman, U.H., Seppälä, M., Laatikainen, T. Fertil. Steril. (1991) [Pubmed]
  28. Molecular approach to common causes of female infertility. Simpson, J.L. Best practice & research. Clinical obstetrics & gynaecology. (2002) [Pubmed]
  29. Platelet activation in patients with benign and malignant ovarian diseases. Landolfi, R., Storti, S., Sacco, F., Scribano, D., Cudillo, L., Leone, G. Tumori. (1984) [Pubmed]
  30. The response of patients with polycystic ovarian disease to human menopausal gonadotropin therapy after ovarian electrocautery or a luteinizing hormone-releasing hormone agonist. Gadir, A.A., Alnaser, H.M., Mowafi, R.S., Shaw, R.W. Fertil. Steril. (1992) [Pubmed]
  31. Insulin hypersecretion together with high luteinizing hormone concentration augments androgen secretion in oral glucose tolerance test in women with polycystic ovarian disease. Anttila, L., Koskinen, P., Jaatinen, T.A., Erkkola, R., Irjala, K., Ruutiainen, K. Hum. Reprod. (1993) [Pubmed]
  32. The source(s) of estrogen production in hirsute women with polycystic ovarian disease as determined by simultaneous adrenal and ovarian venous catheterization. Wajchenberg, B.L., Achando, S.S., Mathor, M.M., Czeresnia, C.E., Giannella Neto, D., Kirschner, M.A. Fertil. Steril. (1988) [Pubmed]
  33. Elevated serum levels of neopterin and soluble interleukin-2 receptor in patients with ovarian cancer. Gadducci, A., Ferdeghini, M., Malagnino, G., Prontera, C., Fanucchi, A., Annicchiarico, C., Bianchi, R., Fioretti, P., Facchini, V. Gynecol. Oncol. (1994) [Pubmed]
  34. Fertility parameters of dairy cows with cystic ovarian disease after treatment with gonadotrophin-releasing hormone. Hooijer, G.A., van Oijen, M.A., Frankena, K., Valks, M.M. Vet. Rec. (2001) [Pubmed]
WikiGenes - Universities